24/7 Market News Snapshot 24 September, 2024 – Capricor Therapeutics Inc (NASDAQ:CAPR)

September 24, 2024

DENVER, Colo., 24 September, 2024 (247marketnews.com) – (NASDAQ:CAPR) are discussed in this article.
Capricor Therapeutics Inc (NASDAQ:CAPR) has recently experienced a significant uptick in its stock performance, jumping to $8.024, a remarkable 34.41% rise from the previous day, accompanied by a trading volume of 1.26 million shares. This surge reflects increased investor enthusiasm and confidence in the company’s future prospects, highlighting the growing market support for its innovative therapies aimed at treating rare diseases.

In a related strategic move, Capricor announced its intent to submit a Biologics License Application (BLA) for deramiocel, a treatment focused on patients with Duchenne muscular dystrophy (DMD) cardiomyopathy. Following fruitful discussions with the U.S. Food and Drug Administration (FDA), the company plans to initiate the BLA rolling submission in October 2024, with a full application expected by the end of the year. The submission will be supported by robust cardiac data from the Phase 2 HOPE-2 trial and relevant natural history data from notable medical institutions, further solidifying its commitment to addressing an unmet medical need.

Linda Marbán, Ph.D., Chief Executive Officer of Capricor, expressed optimism about this pivotal moment, stating that successful development and potential approval of deramiocel could significantly improve treatment options for individuals affected by DMD cardiomyopathy. Currently, no therapies are approved specifically targeting this condition, which has a profound impact on patient longevity and quality of life.

As part of its forward-looking strategy, Capricor is also considering expanding the therapeutic label of deramiocel to include DMD skeletal muscle myopathy. The company’s ongoing commitment to advancing innovative treatments underscores its role as a key player in the rare disease therapeutic landscape, especially as it garners FDA support for its promising solutions.

Related news for (CAPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.